---
title: "BioDefense Therapeutics (BD Tx) completes Phase 2 trials"
description: "CBRNe World provides those tasked with defending against CBRN and IED threats with the essential practical, scientific and political information. Access the current and previous issues of the magazine by registering as a member."
url: "https://cbrneworld.com/news/subscribers/biodefense-therapeutics-bd-tx-completes-phase-2-trials"
date: "2026-07-30T21:07:07+00:00"
language: "en-GB"
---

#  BioDefense Therapeutics (BD Tx) completes Phase 2 trials

 Written by Gwyn Winfield on 11 November 2013.

BD Tx and MediVector announced that Favipiravir (also known, less catchily, as T-705a), their anti-influenza drug, has now passed Phase Two trials and is able to begin Phase Three. The results of their Phase Two trial showed that twice daily dosing of Favipiravir demonstrated statistically lower time to alleviation of each of the six influenza symptoms and that they cleared the virus statistically quicker than the placebo. Favipiravir will hopefully clear Phase Three trials and result in a therapeutic that can deal with multiple strains of drug resistant flu. The team, through the JPEO CBD, is also interested in genetically engineered flu, and is looking at their unique mechanism of blocking viral RNA to see how applicable it would be to that, and other pathogens.

## Schema

```json
{ "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "News", "item": "https://cbrneworld.com/news" }, { "@type": "ListItem", "position": 2, "name": "Subscribers", "item": "https://cbrneworld.com/news/subscribers" }, { "@type": "ListItem", "position": 3, "name": "BioDefense Therapeutics (BD Tx) completes Phase 2 trials", "item": "https://cbrneworld.com/news/subscribers/biodefense-therapeutics-bd-tx-completes-phase-2-trials" } ] }
```

```json
{ "@context": "https://schema.org", "@type": "NewsArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://cbrneworld.com/news/subscribers/biodefense-therapeutics-bd-tx-completes-phase-2-trials" }, "headline": "BioDefense Therapeutics (BD Tx) completes Phase 2 trials", "description": "BD Tx successfully completed their Phase Two double blind, placebo controlled clinical trial for their flu treatment drug", "image": { "@type": "ImageObject", "url": "https://cbrneworld.com/" }, "publisher": { "@type": "Organization", "name": "CBRNe World Magazine", "logo": { "@type": "ImageObject", "url": "https://cbrneworld.com/images/default/Asset%201.png" } }, "author": { "@type": "Person", "name": "Ben Bray", "url": "https://cbrneworld.com/news/subscribers/biodefense-therapeutics-bd-tx-completes-phase-2-trials" }, "datePublished": "2013-11-11T12:18:55+00:00", "dateCreated": "2013-11-11T12:18:55+00:00", "dateModified": "2018-12-14T15:55:28+00:00" }
```